RemeGen

newspaper
Pharma

Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia

Akeso and Summit's ivonescimab bagged its first overall survival win. Fosun inked another licensing deal. Hutchmed's CEO took medical leave. And more.
Angus Liu Aug 29, 2025 8:15am
goal

RemeGen's telitacicept result sets up IgAN submission in China

Aug 27, 2025 11:13am
newspaper

J&J-Fujifilm, drug recalls, RemeGen-Santen—Fierce Pharma Asia

Aug 22, 2025 8:05am
newspaper

Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia

Aug 15, 2025 8:31am
On target clinical trial success bullseye score

RemeGen's telitacicept meets the mark in ph. 3 Sjögren's study

Aug 13, 2025 10:03am
Asia

RemeGen, Harbour, Datroway—Fierce Pharma Asia

Jun 27, 2025 8:37am